Back to Results
First PageMeta Content



Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri
Add to Reading List

Document Date: 2013-06-03 17:45:31


Open Document

File Size: 685,23 KB

Share Result on Facebook
UPDATE